Wyeth Europa Ltd withdraws its marketing authorisation application for
Pristiqs (desvenlafaxine)
The European Medicines Agency (EMEA) has been formally notified by
Wyeth Europa Ltd of its decision to withdraw the application for a
centralised marketing authorisation for the medicine Pristiqs
(desvenlafaxine) 50mg and 100mg prolonged release tablets.
Read more...
http://www.worldpharmanews.com/content/view/334/1/

Trial Date Set For SEROQUEL(R) Patent Litigation
AstraZeneca announced a trial date has been set for patent litigation
in the US District Court for the District of New Jersey against Teva
Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement
of AstraZeneca's patent as a result of Teva's and Sandoz's filings of
Abbreviated New Drug Applications (ANDAs).
Read more...
http://www.worldpharmanews.com/content/view/333/1/

Femara(R) helps protect against return of breast cancer
Women may reduce the risk of their breast cancer returning by starting
treatment with Femara(R) (letrozole) anywhere from one to seven years
after finishing tamoxifen therapy, according to a new analysis
published today in the Journal of Clinical Oncology[1].
Read more...
http://www.worldpharmanews.com/content/view/332/1/

Nycomed intends to move chemical production to Indian joint venture
Nycomed and Cadila Healthcare have signed a letter agreement with the
intent to amend their existing joint venture agreement to include the
chemical production of active pharmaceutical ingredients (APIs) by the
joint venture company Zydus Nycomed in India. Based on this agreement,
Nycomed plans to transfer the current chemical production from the
sites in Linz (Austria) and Singen (Germany) to the new joint venture
within the next three to four years.
Read more...
http://www.worldpharmanews.com/content/view/331/1/

Baxter and its Foundation Contribute Nearly $53 Million in 2007 to
Address Critical Needs
Baxter International Inc. and The Baxter International Foundation, the
philanthropic arm of Baxter, today announced their combined 2007
charitable giving, which focused on increasing access to healthcare,
helping developing nations and countries in crisis, and addressing
other critical community needs.
Read more...
http://www.worldpharmanews.com/content/view/330/1/

A successful 2007 paves the way for future of Nycomed
In 2007 Nycomed increased adjusted EBITDA by 31.0% compared to last
year to a total of EURO 1,222.2 million. The strong performance was
accompanied in the fourth quarter by major advancements in the US out-
licensing efforts that materialised in early 2008. The full year
results benefited from increased sales, especially from high-margin
products as well as a significant reduction in costs.
Read more...
http://www.worldpharmanews.com/content/view/329/1/

ALERT project looks to ICT for drug safety
A new EU-funded information and communication technology (ICT) project
is tackling issues of safety in newly developed drugs. Over the next
three and a half years, the ALERT ('Early detection of adverse drug
events by integrative mining of clinical records and biomedical
knowledge') project partners will work on an innovative computer
system for a better and faster detection of adverse drug reactions
(ADRs).
Read more...
http://www.worldpharmanews.com/content/view/328/1/

Amgen Announces Update to U.S. Prescribing Information for Aranesp(R)
and EPOGEN(R)
Amgen Inc. (NASDAQ:AMGN) announced the U.S. Food and Drug
Administration (FDA) has approved updated safety information,
including an updated boxed warning in the labeling information for the
class of drugs known as erythropoiesis-stimulating agents (ESAs),
including Aranesp(R) (darbepoetin alfa) and EPOGEN(R) (Epoetin
alfa).
Read more...
http://www.worldpharmanews.com/content/view/327/1/

Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex
Pfizer Inc announced today that the Court of Appeals for the Federal
Circuit has upheld the two main U.S. patents covering Celebrex, the
company's selective non-steroidal anti-inflammatory (NSAID) medicine
used to treat pain and inflammation. The patents had been challenged
by generic manufacturer Teva Pharmaceuticals USA.
Read more...
http://www.worldpharmanews.com/content/view/326/1/

World Pharma News .net/Published News

Trial Date Set For SEROQUEL Patent Litigation
http://www.worldpharmanews.net/Product/Trial_Date_Set_For_SEROQUEL%AE_Patent_Lit
igation/

Pharmalot US Rx Sales Grew Just 3.8 Percent In 'O7
http://www.worldpharmanews.net/Financial/Pharmalot_-_US_Rx_Sales_Grew_Just_3-8_P
ercent_In_O7/

Femara helps protect against return of breast cancer
http://www.worldpharmanews.net/Product/Femara%AE_helps_protect_against_return_of
_breast_cancer/

Drug Injury Watch: Tequin Revisited: Health Canada And The FDA Failed
To Take Action, At Our Expense
http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Tequin_Revisited_Health_C
anada_And_The_FDA_Failed_To_Take_Action_At_Our_Expense-1/

Why Big Pharma come to China
http://www.worldpharmanews.net/Corporate/Why_Big_Pharma_come_to_China/

Nycomed intends to move chemical production to Indian joint venture
http://www.worldpharmanews.net/Corporate/Nycomed_intends_to_move_chemical_produc
tion_to_Indian_joint_venture/

Baxter and its Foundation Contribute Nearly $53 Million in 2007 to
Address Critical Needs
http://www.worldpharmanews.net/Corporate/Baxter_and_its_Foundation_Contribute_Ne
arly_53_Million_in_2007_to_Address_Critical_Needs/

Drug find worth $700 million -- chicagotribune.com
http://www.worldpharmanews.net/Product/Drug_find_worth_700_million_-_chicagotrib
une-com/

A successful 2007 paves the way for future of Nycomed
http://www.worldpharmanews.net/Financial/A_successful_2007_paves_the_way_for_fut
ure_of_Nycomed/

ALERT project looks to ICT for drug safety
http://www.worldpharmanews.net/Research_Development/ALERT_project_looks_to_ICT_f
or_drug_safety/